Shenzhen Mindray (300760 CH): Sustained Growth Momentum; China Recovery To Provide Further Filip

310 Views03 Oct 2024 15:53
​Shenzhen Mindray sees double-digit growth in sales and net profit in 1H24, driven by in-vitro diagnostics and medical imaging systems. With 18% sales growth, international market outperforms China.
What is covered in the Full Insight:
  • Introduction to Shenzhen Mindray
  • Company Background and Global Presence
  • Financial Performance Highlights 1H24
  • Segment Analysis: International vs Domestic Markets
  • Research and Development Focus and Future Outlook
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Rising
Tina Banerjee
Global Healthcare Analyst
Health CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x